💶 🚨 SciRhom has secured a EUR 63 Million Series A financing to accelerate iRhom2-targeting therapies in autoimmune diseases. ⬇ The financing enables us to shift gears and accelerate our novel and potentially groundbreaking therapeutic strategy toward clinical proof-of-concept and beyond to reach patients in need of better autoimmune treatments. SciRhom aims to push the boundaries in autoimmune medicine by addressing TACE/ADAM17, a master switch for various autoimmune disease-relevant signaling pathways, via iRhom2. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including HTGF | High-Tech Gründerfonds and the US-based PhiFund Ventures. We are excited to have attracted such a high-caliber international consortium of investors and appreciate our existing shareholders backing SciRhom in this crucial period of its development. In conjunction with this investment, we are excited to welcome Olivier Litzka, Peter Neubeck, Georgina Askeland, PhD, Dr. Fei Tian, and Varun Gupta to SciRhom’s Board of Directors and look forward to collaborating with them. Stay tuned and follow us here on LinkedIn to learn more about our novel approach as we progress toward initiation of a first clinical study in H2 2024. #venturecapital #financing #funding #fundingalert #SeriesA #iRhom2 #ADAM17 #TACE #autoimmune #IBD #RA #drugdiscovery #antibodyresearch #munichbiotech
Info
SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases.
- Website
-
http://www.scirhom.com
Externer Link zu SciRhom
- Branche
- Biotechnologieforschung
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Martinsried
- Art
- Privatunternehmen
- Gegründet
- 2016
- Spezialgebiete
- drug development, targeted therapy und drug discovery
Orte
-
Primär
Wegbeschreibung
Am Klopfspitz 19
Martinsried, 82152, DE
Beschäftigte von SciRhom
-
Vijay Nair
Managing Director @ HSS | driving innovation, partnerships, and investments to help our patients move and live better
-
Jens Ruhe
Co-Founder, Chief Operating Officer, Managing Director
-
Wolfgang Baiker
Seasoned Pharmaceutical Executive with more than 30 years experience in Development, Manufacturing, Quality, Strategy and General Management. Board…
-
Kerstin Selle
Head Drug Discovery bei SciRhom GmbH
Updates
-
📢 One big step closer to evaluating our first #iRhom2-targeting therapeutic antibody in human studies. ⬇ The approval of a clinical trial application by the Austrian regulatory authorities (BASG/AGES) for our development program SR-878 paves the way for the upcoming clinical study in the second half of 2024. SR-878 targets iRhom2, a crucial regulator of TACE/ADAM-17, which is a master switch for various disease-relevant signaling pathways. In the upcoming study, we aim to evaluate safety in healthy volunteers and provide initial evidence of clinical activity in a second part of the study. Stay tuned for more on SciRhom’s unique approach for breaking through the therapeutic ceiling in autoimmune diseases. #iRhom #iRhom2 #TACE #ADAM17 #IBD #arthritis #clinicalresearch #autoimmune
-
SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases. A special thank you goes to our team and partner WuXi Biologics and other vendors for their exceptional work and collaboration. Find more information on https://scirhom.com #innovation #clinicaltrial #scirhom #arthritis #ibd #biologics #biotech
-